Member Info for Moorscloud

Thank you for the considered, informative response, John. As you've doubtless realised, I personally am looking at Poly as a long-term divi/income provider and even as this is delayed, the "higher group profits and falling debt" will presumably be reflected in eventual dividends as well as the sp. Do you feel then Poly's concern about the penalties is holding them back from attracting buyers or could it be that a sale is actually actively being sought at this time?

John - you said recently "Penalty will have to be paid, and me thinks it may be a too heavy a price to pay, which will leave POLY with no option but to stay put till the conflict ends." Tragically for the people and country of Ukraine, it is hard to see this resolving at all yet alone soon. Hoping this doesn't sound too trite and selfish but is there any way the dividends could be paid without the sale or end of the conflict and if not, do you think shareholders will start to drift away from Poly without them - and would Poly care if so..?

Some Saturday night wonderings as Hemo excitement bubbles :)

Taking it somewhat as read that Hemo is going clinical in the very/pretty/quite near future, I remember HH (I think) giving a very useful summary of the chances of getting through each clinical stage - over 80% of success at phase 1 as I recall. Has as anyone got thoughts on how long phase 1 trials generally take? Also wondering which is generally deemed to have the greater effect on the sp: going clinical in the first place or getting to phase 2 trials?

May all long-termers get the rewards their loyalty, faith and tenacity deserve!

And, scarcely here a year, all thanks for sharing your knowledge and helping to keep us newbies on the path to Hemo-glory

How come MyIPA gets 3 goes??? lol

Great update/summary by JHFH this morning - needs passing on all those people we know who deserve the Hemo-glow :)

Okay it wasn't this Thursday (at 7am anyway) but why not Thursday next week or the following - as indeed chosen by HH. Normal statistics for Hemo rnss can't be relevant for this new territory and maybe it is "rude" to submit an application to the FDA on a Thursday but I can't see Vlad taking offence at receiving approval on any day. Or indeed at ANY time on ANY day. All we do know - for certain - is that it's coming. And soon. GLA.

Appreciate what you’re saying about Tempest, Saint. It’s great to hear about that magical event but it’s also grounding to hear why it’s not so likely in Hemo’s case. And “just” JHFH’s 1000% at this time would be so so pleasing :)

Laughable.

Gosh, not sure quite as many would join in that game..

Great game JHFH - updated list please :)

I now like Tuesdays: 30th Jan :)

Hulver - have to admit this is beyond me and my ignorant response is concern whereas your posting seems positive so wondering what are your thoughts on your final questions and indeed how the market could view such funding?

Great and rather funny getting the statistic-defying rns this Tuesday morning :)

More seriously, it does seem clear that Vlad is not interested in acting to please shareholders and that he is driven mostly by the desire for the success of his scientific works. And clearly going clinical is an absolute key to moving forward not just with CAR-T but also CDX and CBR so Vlad perhaps wants this even more than us!

Possibly also an RNS with conference news at any time in addition to CBR update?

All could hardly be better then :)

Didn't even bother to check in at 7 am this morning as sure rns wouldn't come on a Tuesday but will check in every 7am from now on! Great update JHFH, very very excited is such a good summary and feeling :)

Just wondering, are Prevail solely involved with CAR-T or do you think they could also have direct or indirect positive effects on the future paths of CDX / CBR?

Coco - or both :)

Thank you Hulver - most encouraging and informative as ever.

Hulver - can I ask to what extent do you think further investment in BAIT / CDX is already likely to be in the pipeline or will this investment be dependent on the FDA approval of the CAR-T IND?